Complement C3 is a novel modulator of the anti-factor VIII immune response

Development of neutralizing antibodies against therapeutic Factor VIII (FVIII) is the most serious complication of the treatment of hemophilia A. There is growing evidence to show the multifactorial origin of the anti-FVIII immune response, combining both genetic and environmental factors. While a r...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Haematologica
Auteurs principaux: Rayes, Julie, Ing, Mathieu, Delignat, Sandrine, Peyron, Ivan, Gilardin, Laurent, Vogel, Carl-Wilhelm, Fritzinger, David C., Frémeaux-Bacchi, Véronique, Kaveri, Srinivas V., Roumenina, Lubka T., Lacroix-Desmazes, Sébastien
Format: Artigo
Langue:Inglês
Publié: Ferrata Storti Foundation 2018
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5792280/
https://ncbi.nlm.nih.gov/pubmed/29146705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2017.165720
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires